Originally published in icon Issue 1 2007
The British Journal of Haematology (Jan 2006) reports on clinical trials held by the Urinary Oncology Department at Memorial Sloan-Kettering, New York where a new drug called Asentar - a pharmaceutically developed concentrated vitamin D - significantly improved survival times.
Dr Howard Scher, team leader, ran a trial involving 250 prostate cancer patients. In all cases, conventional hormone therapy had stopped working. Patients took the Vitamin D drug for three weeks, with a fourth week’s pause, in combination with Taxotere - and life expectancy increased from 16.5 to over 24 months. Thrombic side effects of Taxotere also reduced by 34 per cent. No side effects for Asentar were reported.
At Last - the definitive, research based book on how to build a diet to help beat cancer. Click here to read about it.
A Phase III trial is now taking place, with over 900 patients, as this vitamin D synthetic concentrate still needs license approved. Dr Scher said, “It has enormous potential”. (Ed: Vitamin D always has had enormous potential – if only most UK oncologists would stop ignoring it)